Shares of biotech Agenus (NASDAQ: AGEN) appreciated almost 5% today, after the company posted its 3rd quarter earnings. The company's key compound, QS-21 Stimulon, is licensed to some of the biggest players in the pharmaceutical space, ,including GlaxoSmithKline (GSK +0.56%) and Janssen, which is a subsidiary of Johnson & Johnson (JNJ +0.46%).
In the following video, health care analysts Max Macaluso and David Williamson discuss the company's latest quarter and a few things Agenus investors should watch.
